Amarillo Biosciences is a specialty biopharmaceutical company developing a patented formulation of interferon-alpha that's given orally in low doses, making it safer and less expensive than current injectable formulations.
Amarillo Biosciences is working with global partners to conduct clinical studies to establish the safety and efficacy of low-dose interferon-alpha given in the form of orally dissolving lozenges to treat a number of significant human diseases, including influenza and hepatitis C
